// changes done below on July 01 2024 // till here on July 01 2024

Top 10 ADC Companies

Published: March 2024


The future success of the antibody drug conjugates market hinges on key industry stakeholders' strategic efforts to capitalize on growth trends and meet rising demand for such therapeutics. We analyzed over 145 companies that are engaged in the development of antibody drug conjugates. In this article, discover top 10 ADC companies and their antibody drug conjugates therapeutic pipeline.


Cancer is one of the leading causes of mortality, accounting for 0.6 million deaths in 2022, in the US alone. Further, as per the International Agency for Research on Cancer (IARC), by 2040, there are likely to be 27.5 million new cases and 16.3 million deaths related to cancer, annually. Amongst various targeted therapies being evaluated for cancer, antibody drug conjugates (ADCs) have emerged as a highly potent option to selectively eliminate tumor cells with minimal side effects. These are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic drug. Such conjugates are believed to be more efficient and effective in specifically identifying and eliminating cells / pathogens that are associated with the disease(s). Despite the challenges associated with the development and manufacturing of such interventions, they are still considered as a revolutionary technology over their components, such as the naked monoclonal antibodies and drugs (cytotoxins).

The ongoing research activity in this field has led to the discovery of several novel molecular targets, further strengthening the research pipelines of companies engaged in this market. Currently, several industry and non-industry players are focused on the development of technologies that are capable of overcoming the existing roadblocks in the production / adoption of antibody drug conjugates. Driven by the availability of innovative technology platforms, lucrative funding opportunities and encouraging clinical trial results, the ADC companies are poised to reap benefits in the long-run, as multiple product candidates are expected to receive marketing approval in the coming decade.

Roots Analysis has conducted an exhaustive study on Antibody Drug Conjugate Market featuring the current market landscape and future opportunity for the companies developing antibody drug conjugates, over a span of 12 years.

Table of Contents

Below, we have listed (in alphabetical order), the 10 top ADC companies.

  1. ADC Therapeutics
  2. Astellas Pharma
  3. AstraZeneca
  4. Byondis
  5. Daiichi Sankyo
  6. Genentech
  7. Gilead Sciences
  8. ImmunoGen
  9. Pfizer
  10. Seagen

Top 10 ADC Companies

Interested in exploring all 145+ antibody drug conjugate companies and their recent initiatives?

Discover Below the Details on 10 Top ADC Companies

Let us deep dive to understand the activity of the top ADC companies (shortlisted on the basis of therapeutic portfolio / ADC pipeline). It is essential to note that the selection of top players can differ substantially according to the defined criteria.

ADC Therapeutics is Revolutionizing Oncology Treatment with its Innovative PBD-based Antibody Drug Conjugates

1. ADC Therapeutics

ADC Therapeutics is a biotechnology company engaged in the development of Pyrrolobenzodiazepine (PBD)-based antibody drug conjugates intended specifically for the treatment of hematological cancers and solid tumors. In addition, the company’s proprietary PBD dimers have been designed to reduce drug resistance.

ADC Therapeutics: Company Details

Key Parameters Discription
Headquarter ADC Therapeutics - Headquarter
Year of Establisment   2011
Number of Employees  201-500
Key Executives 
  • Ameet Mallik (Chief Executive Officer and Director)
  • Jose Carmona (Chief Financial Officer)
  • David Gilman (Chief Business and Strategy Officer)
  • Peter Graham (Chief Legal Officer)
  • Kristen Harrington-Smith (Chief Commercial Officer)
  • Michael Mulkerrin (Chief Technical Operations Officer)
  • Kimberly Pope (Chief People Officer)
  • Susan Romanus (Chief Compliance and Quality Officer)
  • Patrick van Berkel (Chief Scientific Officer) 
  • Mohamed Zaki (Chief Medical Officer)


ADC Therapeutics: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Zynlonta / loncastuximab tesirine / ADCT-402 CD19 Diffuse large B-cell lymphoma Approved
2 Camidanlumab tesirine / ADCT-301 CD25 Acute myeloid leukemia, Myelodysplastic syndrome,
Myeloproliferative neoplasm, Hodgkin’s lymphoma
Phase II
3 Epratuzumab Tesirine / ADCT-602 CD22 Acute lymphoblastic leukemia Phase I / II
4 Mipasetamab Uzoptirine / ADCT-601 AXL Protein Non-small cell lung cancer, Solid tumor (Unspecified) Phase I
5 ADCT-901 KAAG1 Ovarian cancer, Breast cancer Phase I
6 ADCT-701 DLK-1 Neuroblastoma, Hepatocellular carcinoma, Small cell lung cancer,
Acute myeloid leukemia
Preclinical
7 ADCT-212 PSMA Prostate cancer Preclinical


Recent Development: In December 2023, ADC Therapeutics announced the initial results from a phase 2 clinical trial evaluating its approved ADC ZYNLONTA® in combination with Rituximab. The treatment will be evaluated in patients with relapsed / refractory follicular lymphoma.

Further details on recent initiatives taken by ADC Therapeutics as well as other ADC companies have been provided in detail in the report.

Astellas Pharma is Innovating at the Crossroads of Immunology, Nephrology, Oncology, and Urology

2. Astella Pharma

Astellas Pharma is a Japan based biopharmaceutical company, which specializes in the manufacturing and commercialization of novel pharmaceuticals intended for the treatment of indications across several therapeutic areas, including immunology, nephrology, oncology and urology. The company claims to have a global presence and operates through its subsidiaries based in the US, Europe and some of the Asian countries.

Astellas Pharma: Company Details

Key Parameters Discription
Headquarter Astellas Pharma - Headquarter
Year of Establisment   2005
Number of Employees  10,001+
Key Executives 
  • Kenji Yasukawa (Chief Executive Officer, Director and President)
  • Naoki Okamura (Chief Strategy Officer, Director and Executive Vice President)
  • Yukio Matsui (Chief Commercial Officer)
  • Yoshitsugu Shitaka (Chief Scientific Officer)
  • Minoru Kikuoka (Chief Financial Officer)
  • Hideki Shima (Chief Manufacturing Officer)
  • Tadaaki Taniguchi (Chief Medical Officer)
  • Katsuyoshi Sugita (Chief People Officer, Chief Ethics and Compliance Officer)


Astellas Pharma: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Padcev / Enfortumab vedotin Nectin-4 Locally advanced or metastatic urothelial cancer Approved
2 AGS 67 E CD37 Lymphoid cancer Phase I


Recent Development: In January 2024, Astellas Pharma submitted the Supplemental New Drug Application in Japan for a combination therapy of PADCEV™ (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as first-line treatment of advanced bladder cancer.

Further details on recent initiatives taken by Astellas Pharma as well as other ADC companies have been provided in detail in the report.

AstraZeneca is Merging Science and Technology to Battle the World's Most Pressing Medical Challenges

3. AstraZeneca

AstraZeneca was formed as a result of a merger of the companies, Astra of Sweden and the Zeneca Group of the UK. Amongst other synergies, the merger strengthened the research pipeline and resulted in a wider distribution network, helping the merged entity to add novelty and innovation to its portfolio. In 2007, the company acquired MedImmune, which is currently a wholly owned subsidiary of AstraZeneca, handling the R&D aspects of biologics. Some of the company’s key focus areas include oncology, cardiovascular and metabolic disorders, and respiratory diseases. In addition to this, the company is involved in developing drugs for treating autoimmune disorders, neurological disorders and infectious diseases. The firm claims to have built a strong pipeline for the immuno-oncology market, which is expected to be commercialized in the near future.

AstraZeneca: Company Details

Key Parameters Discription
Headquarter AstraZeneca - Headquarter
Year of Establisment   1999
Number of Employees  10,001+
Key Executives 
  • Pascal Soriot (Executive Director and Chief Executive Officer)
  • Aradhana Sarin (Executive Director and Chief Financial Officer)
  • Marc Dunoyer (Chief Strategy Officer)
  • Jeff Pott (Chief Human Resources Officer, Chief Compliance Officer)


AstraZeneca: Antibody Drug Conjugate Pipeline

S.No. Drug Target Indication Highest Status
of Development 
1 Enhertu / Trastuzumab deruxtecan /
DS-8201a / DS 8201
ERBB2
  • Unresectable or metastatic HER2-positive breast cancer in patients that have received two
    or more prior anti-HER2-based regimens
  • Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal
    adenocarcinoma who have received a prior trastuzumab-based regimen
  • Adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have
    activating HER2 mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Approved
2 AZD8205 B7-H4 (VTCN1) Advanced or metastatic solid malignancies Phase I / II
3 AZD9592 EGFR, c-MET Solid tumor Phase I
4 MEDI2228 BCMA (TNFRSF17 / BCM) Multiple myeloma Phase I


Recent Development: In January 2024, AstraZeneca (and Daiichi Sankyo) announced that the USFDA is reviewing ENHERTU® (fam-trastuzumab deruxtecan-nxki) for treatment of any solid tumor with a specific genetic signature, and therefore, it could become First Tumor-Agnostic HER2-Targeting ADC. The drug is being reviewed under Real-Time Oncology Review (RTOR) program and Project Orbis, two initiatives of the USFDA that are designed to bring safe and effective cancer treatments to patients as soon as possible.

Further details on recent initiatives taken by AstraZeneca as well as other ADC companies have been provided in detail in the report.

Byondis, is Redefining Cancer Treatment With Breakthrough Innovations

4. Byondis

Byondis is a Netherlands-based clinical stage biopharmaceutical company focused on the development of novel antibody drug conjugates and monoclonal antibody therapeutics for the treatment of various indications, including oncological disorders and autoimmune disorders. The firm has developed two proprietary technologies, namely ByonZine (a duocarmazine linker-drug technology capable of enhancing stability and efficacy of antibody drug conjugates) and ByonShieLD (a site-specific antibody-conjugation technology for enhancing antitumor activity of antibody drug conjugates).

Byondis: Company Overview

Key Parameters Discription
Headquarter Byondis - Headquarter
Year of Establisment   2012
Number of Employees  201-500
Key Executives 
  • Jacques Lemmens (Founder / Chairman of the Board)
  • Marco Timmers (Chief Executive Officer)
  • Wim Dokter (Chief Scientific Officer)
  • Jan Schellens (Chief Medical Officer)
  • Aad van de Leur (Chief Operations Officer)
  • Hans Pegt (Chief Legal Officer)
  • Robbert van Heekeren (Chief Financial Officer)


Byondis: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Trastuzumab duocarmazine / SYD985 HER-2 (ERBB2) HER2-positive breast cancer BLA Submitted
2 BYON3521 c-MET Solid tumor (Unspecified) Phase I
3 SYD1875 5T4 Solid tumor (Unspecified) Phase I
4 BYON4413 CD123  Undisclosed Preclinical


Recent Development: In May 2022, the company entered into an agreement with medac for the commercialization of trastuzumab duocarmazine (SYD985) against multiple indications, across Europe.

Further details on recent initiatives taken by Byondis as well as other ADC companies have been provided in detail in the report.

Daiichi Sankyo is Embarking on a $22 billion Journey with Merck to Transform Cancer Care

5. Daiichi Sankyo

Daiichi Sankyo is a global research-based pharmaceutical company providing its services in more than 25 countries.  It has a diverse portfolio, which includes innovative and generic pharmaceuticals, vaccines and over-the-counter drugs.  The company uses its proprietary antibody drug conjugate technology to develop a wide range of antibody drug conjugate products. Enhertu and datopotamab deruxtecan are the leading antibody drug conjugates developed by the company.  It is worth mentioning that, in January 2021, Enhertu received the Prime Minister Award from Japan-Techno Economics Society.

Daiichi Sankyo: Company Overview

Key Parameters Discription
Headquarter Daiichi Sankyo - Headquarter
Year of Establisment   2007
Number of Employees  10,000+
Key Executives 
  • Sunao Manabe (Chief Executive Officer and Executive Chairperson)
  • Masahiko Ohtsuki (Chief Digital Transformation Officer, Director and Senior Executive Office)
  • Hiroyuki Okuzawa (Chief Operational Officer, Representative Director and President)

 

Daiichi Sankyo: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Enhertu / Trastuzumab deruxtecan / DS-8201a / DS 8201 HER2
  • Patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.
  • Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
  • Adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Approved
2 Datopotamab deruxtecan / DS-1062 TROP2 Non-small cell lung cancer, Breast cancer Phase III
3 Patritumab deruxtecan / U3-1402 HER3 Non-small cell lung cancer Phase III
4 Ifinatamab deruxtecan / DS-7300A B7-H3 Small-cell lung cancer Phase II
5 DS-6157 GPR20 Gastrointestinal stromal tumor Phase I
6 DS-6000 CDH6 Renal cancer, Ovarian cancer Phase I
7 Undisclosed TA-MUC1 Undisclosed Preclinical


Recent Development: In October 2023 Daiichi Sankyo signed USD 22 billion deal with Merck for the co-development and commercialization of 3 ADCs; these include: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd).

Further details on recent initiatives taken by Daiichi Sankyo as well as other ADC companies have been provided in detail in the report.

Genentech is Revolutionizing Lymphoma Treatment with Landmark FDA Approval

6. Genetech (Subsidiary of Roche)

Genentech, a wholly owned subsidiary of Roche since 2009, claims to be one of the leading biotech companies with a promising development pipeline that aims to discover best-in-class therapeutics.

Genentech: Company Overview

Key Parameters Discription
Headquarter Genentech - Headquarter
Year of Establisment   1976
Number of Employees  10,001+
Key Executives 
  • Alexander Hardy (Chief Executive Officer)
  • Levi Garraway (Chief Medical Officer)
  • Ed Harrington (Chief Financial Officer)
  • Cori Davis (Chief People Officer)
  • Sean Johnston (Chief Compliance Officer)


Genentech: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Kadcyla / Trastuzumab emtansine HER-2 (ERBB2) HER2-positive Early Breast Cancer Approved
2 Polivy / Polatuzumab vedotin CD79b Relapsed or Refractory Diffuse Large B-cell Lymphoma Approved


Recent Development: In April 2023, Genentech made an announcement regarding the USFDA approval of POLIVY® (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP). This approval pertains to the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) who have an International Prognostic Index (IPI) score of two or greater.

Further details on recent initiatives taken by Genentech as well as other ADC companies have been provided in detail in the report.

Gilead Sciences is Accelerating Cancer Therapy with Groundbreaking Clinical Study Partnership

7. Gilead Sciences

Gilead Sciences is a US based biopharmaceutical company, focused on the research and development of novel therapeutic interventions for conditions with unmet medical needs. The company’s portfolio comprises of products for the treatment of several disorders, such as HIV/AIDS, cancer, inflammatory conditions, and cardiovascular diseases.

Gilead Sciences: Company Overview

Key Parameters Discription
Headquarter Gilead Sciences - Headquarter
Year of Establisment   1987
Number of Employees  10,001+
Key Executives 
  • Daniel O’Day (Chairman and Chief Executive Officer)
  • Andrew Dickinson (Chief Financial Officer)
  • Johanna Mercier (Chief Commercial Officer)
  • Merdad Parsey (Chief Medical Officer)
  • Christi Shaw (Chief Executive Officer, Kite)


Gilead Sciences: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Trodelvy / Sacituzumab govitecan-hziy / IMMU-132 / GS-0132 TROP-2 Triple negative breast cancer, Urothelial cancer Approved
2 Labetuzumab govitecan / IMMU-130 CEACAM4 Metastatic colorectal cancer Phase I


Recent Development: In December 2023, Gilead Sciences announced clinical study partnership with IDEAYA Biosciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer.

Further details on recent initiatives taken by Gilead Sciences as well as other ADC companies have been provided in detail in the report.

ImmunoGen, One of the Pure Play ADC Companies, Became a Target for $10.1 billion Acquisition by AbbVie

8. ImmunoGen

ImmunoGen claims to be one of the leading players in the antibody drug conjugates domain, specializing in the development of novel, targeted antibody-based therapeutics for the treatment of cancer. The company develops a wide range of antibody drug conjugate products using its proprietary antibody drug conjugate technology. In addition to this, it has out licensed its antibody drug conjugate technology to several companies, including Amgen, Genentech / Roche, Eli Lilly, Novartis, Sanofi and Takeda. It is interesting to highlight that Roche’s marketed ADC product, KADCYLA was developed using ImmunoGen’s antibody drug conjugate technology.

ImmunoGen: Company Overview

Key Parameters Discription
Headquarter ImmunoGen - Headquarter
Year of Establisment   1981
Number of Employees  201-500
Key Executives 
  • Mark Enyedy (Chief Executive Officer and President)
  • Anna Berkenblit (Chief Medical Officer)
  • Daniel Char (Chief Legal Officer)
  • Stacy Coen (Chief Business Officer)
  • Renee Lentini (Chief Accounting Officer, and Interim Chief Financial Officer)
  • Isabel Kalofonos (Chief Commercial Officer)


ImmunoGen: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Elahere / IMGN853 / Mirvetuximab soravtansine FOLR1 Frα positive, platinum-resistant epithelial ovarian, Fallopian tube, Primary peritoneal cancer Approved
2 Kadcyla / Trastuzumab emtansine HER-2 (ERBB2) Adjuvant treatment of patients with HER2-positive early breast cancer Approved
3 Tusamitamab ravtansine / SAR408701 CEACAM5 Non-small cell lung cancer Phase III
4 Pivekimab sunirine CD123 Blastic plasmacytoid dendritic cell neoplasm, Acute myeloid leukemia Phase I / II
5 IMGC936 ADAM9 Advanced solid tumor Phase I / II
6 IMGN151 FOLR1 Recurrent endometrial cancer and recurrent, High-grade serous epithelial ovarian, Primary peritoneal, Fallopian tube cancer Phase I
7 BSI-709 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
8 BSI-712 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
9 BSI-715 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
10 OBT035 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
11 OBT227 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
12 OBT417 Undisclosed Solid tumor (Unspecified) Discovery / Preclinical
13 Undisclosed Undisclosed Solid tumor (Unspecified) Discovery / Preclinical


Recent Development: In November 2023, AbbVie announced the plan for acquisition of ImmunoGen to enter into the commercial market for ovarian cancer. Under the terms of agreement, AbbVie is expected to acquire all outstanding shares of ImmunoGen at a price of USD 31.26 per share in cash, or a total equity value of about USD 10.1 billion.

Further details on recent initiatives taken by ImmunoGen as well as other ADC companies have been provided in detail in the report.

Pfizer is Fueling Cancer Innovation with a $1.05 billion Licensing Agreement for HBM9033

9. Pfizer

Pfizer is a US-based multi-national pharmaceutical company that develops immunological drugs, drugs targeting rare disorders and oncological disorders, along with vaccines. The company has been listed on various stock exchanges including New York (PFE), London (PFZ), Euronext and Swiss. In 2009, the company acquired Wyeth Pharmaceuticals and inherited the capabilities required for discovery and development of antibody drug conjugates.

Pfizer: Company Overview

Key Parameters Discription
Headquarter Pfizer - Headquarter
Year of Establisment   1849
Number of Employees  10,001+
Key Executives 
  • Albert Bourla (Chief Executive Officer)
  • Sally Susman (Chief Corporation Affairs Officer)
  • Payal Sahni Becher (Chief Human Resources Officer)
  • William Pao (Chief Development Officer)
  • Mike McDermott (Chief Global Supply Officer)
  • Aamir Malik (Chief Business Innovation Officer)
  • Rady Johnson (Chief Compliance, Quality and Risk Officer)
  • Lidia Fonseca (Chief Digital and Technology Officer)
  • Mikael Dolsten (Chief Scientific Officer)
  • Dave Denton (Chief Financial Officer)
  • Angela Hwang (Chief Commercial Officer)


Pfizer: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 Mylotarg / Gemtuzumab ozogamicin CD33 CD33-positive AML who have experienced a relapse or who have
not responded to initial treatment.
Approved
2 Besponsa / Inotuzumab ozogamicin CD22 Relapsed or refractory B-cell precursor acute lymphoblastic leukemia Approved
3 Cofetuzumab pelidotin / ABBV-647 / PF-06647020 PTK7 Solid tumor, non-small cell lung cancer Phase I
4 PF-06688992 GD3 Melanoma Phase I
5 PF-06804103 HER-2 Her2-positive and negative solid tumor Phase I


Recent Development: In December 2023, Pfizer entered into a licensing agreement with Nona Biosciences to develop HBM9033, a mesothelin-targeting antibody-drug conjugate for the treatment of solid tumors. Under the terms of the agreement, Pfizer will make an upfront payment of USD 53 million to Nona Biosciences, as well as near-term payments. Additionally, Pfizer has committed to providing up to USD 1.05 billion in funding for certain development and commercial milestones.

Further details on recent initiatives taken by Pfizer as well as other ADC companies have been provided in detail in the report.

Seagen, a Pioneer in Cancer Care, Acquired by Pfizer for $43 billion

10. Seagen

Seagen, formerly known as Seattle Genetics, is a fully owned subsidiary of Pfizer, focused on the discovery, development and commercialization of anticancer therapies. With 10 novel targeted therapies in different stages of clinical development, the firm aims to expand its pipeline by developing potential antibody-based therapies for the treatment of cancer. The firm claims to have developed a proprietary antibody drug conjugate technology for linking cytotoxic agents to monoclonal antibodies. In addition, the technology has been out-licensed to various other players involved in the development of antibody drug conjugates.

Seagen: Company Overview

Key Parameters Discription
Headquarter Seagen - Headquarter
Year of Establisment   1998
Number of Employees  1,001-5,000
Key Executives 
  • David R Epstein (Chief Executive Officer)
  • Vaughn Himes (Chief Technical Officer)
  • Natasha Hernday (Chief Business Officer)
  • Todd Simpson (Chief Financial Officer)
  • Jean Liu (Chief Legal Officer)


Seagen: Antibody Drug Conjugate Pipeline

S.No. Drug Target          Indication  Highest Status of Development 
1 ADCETRIS / Brentuximab Vedotin CD30
  • Previously untreated systemic anaplastic large cell lymphoma (SALCL) or
    other CD30-expressing peripheral T-cell lymphomas (PTCL)
  • Previously untreated stage III or IV classical Hodgkin lymphoma (CHL), in combination with doxorubicin,
    vinblastine and dacarbazine
  • CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy
Approved
2 TIVDAK / Tisotumab vedotin Tissue factor Recurrent or metastatic cervical cancer that has progressed on or following chemotherapy Approved
3 PADCEV/ Enfortumab vedotin-ejfv Nectin 4 Locally advanced or metastatic urothelial cancer Approved
4 SGN-LIV1A / Ladiratuzumab vedotin LIV-1 Breast cancer Phase II
5 SGN-ALPV ALPP, ALPPL2 Solid tumor (Unspecified) Phase I
6 SGN-B6A Integrin Beta 6 Solid tumor (Unspecified) Phase I
7 SGN-B7H4V B7-H4 (VTCN1) Solid tumor (Unspecified) Phase I
8 SGN-CD228A CD228 Solid tumor (Unspecified) Phase I
9 SGN-PDL1V PD-L1 Solid tumor (Unspecified) Phase I
10 SGN-STNV STN Solid tumor (Unspecified) Phase I


Recent Development: In December 2023, Pfizer completed the acquisition of Seagen for USD 43 billion to accelerate the development of anti-cancer therapeutics including next generation of ADCs.

Further details on recent initiatives taken by Seagen as well as other ADC companies have been provided in detail in the report.

What About the Other ADC Companies Around the World?

The above presentation features ten top ADC companies selected from a pool of over 145 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

About Author

Ronit_Sharma

Ronit Sharma is an accomplished business research and competitive intelligence professional with about seven years of experience in the pharmaceutical and healthcare industry. As a team leader at Roots Analysis, he has authored numerous multidisciplinary market research reports, and led the efforts on several bespoken consulting assignments, providing valuable insights into the latest innovations in healthcare and the digital transformation of the pharmaceutical industry. Ronit's exceptional analytical skills and strategic thinking in the field contribute to the firm's intellectual capital, empowering clients to make informed decisions in the dynamic pharmaceutical landscape. With a passion for staying at the forefront of industry advancements, Ronit specializes in identifying emerging opportunities for various stakeholders, leveraging his deep understanding of market trends and technological developments. He is committed to fostering an environment of excellence, creativity, and innovation within his team, encouraging collaboration and empowering team members to bring their best ideas to the table.

Ronit holds a B. Tech degree in Biotechnology from Lovely Professional University and his research and thought leadership can be found in his professional blog and social media profiles, where he shares the latest insights and engages in meaningful discussions with industry peers. To ensure the highest ethical standards, Ronit openly declares no conflicts of interest in his work, ensuring unbiased and trustworthy contributions. His insights undergo rigorous editorial and peer-review processes, establishing his credibility as a thought leader within the pharmaceutical and healthcare domain. Ronit's exceptional analytical and strategic thinking skills, coupled with his commitment to excellence, make him a valuable asset to any organization in the pharmaceutical and healthcare industry.

Email: ronit.sharma@rootsanalysis.com
LinkedIn: https://www.linkedin.com/in/ron001/

Sources

  1. https://www.globenewswire.com/news-release/2023/12/12/2794525/0/en/ADC-Therapeutics-Announces-Initial-Results-from-Investigator-Initiated-Phase-2-Clinical-Trial-Evaluating-ZYNLONTA-in-Combination-with-Rituximab-in-Patients-with-Relapsed-Refractory.html
  2. https://www.astellas.com/en/news/28851
  3. https://www.prnewswire.com/news-releases/byondis-and-medac-enter-into-license-and-collaboration-and-supply-agreements-for-anti-her2-adc-trastuzumab-duocarmazine-syd985-301538270.html
  4. https://www.pharmaceutical-technology.com/news/msd-signs-up-daiichi-sankyo-in-multibillion-dollar-deal-to-develop-adcs/?cf-view
  5. https://www.labiotech.eu/trends-news/fda-approves-genentech-lymphoma-drug/
  6. https://www.prnewswire.com/news-releases/ideaya-announces-clinical-study-collaboration-with-gilead-sciences-to-evaluate-trodelvy-and-ide397-combination-in-mtap-deletion-bladder-cancer-302003940.html
  7. https://www.pharmtech.com/view/abbvie-to-acquire-immunogen-in-deal-valued-at-10-1-billion
  8. https://www.biospace.com/article/pfizer-inks-potential-1b-adc-deal-with-nona-closes-seagen-acquisition/
  9. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen
  10. https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry